检索结果-南通市图书馆

Correlation of human immunodeficiency virus and antiretroviral therapy with cardiac disorders

Global Health Journal 2023年第3期7卷 130-136页

作者： Riya Sharma Mandeep kaur Department of Pharmacy Practice ISF College of PharmacyMogaPunjab 142001India

The occurrence of cardiovascular illness in the human immunodeficiency virus(HIV)community is increasing,with a particular focus on coronary heart *** infected with HIV have a higher risk of myocardial infarction compared to the general population in modern countries due to the development of effective antiretroviral medications and increased life *** not receiving highly active antiretroviral therapy(ART)may experience common cardiac consequences,including myocarditis,dilated cardiomyopathy,endocarditis,pulmonary hypertension,pericardial effusion,and cardiotoxicity associated with non-antiretroviral *** the use of highly active ART,continuing immune activation and systemic inflammation seem to play a central role in this *** studies suggest that protease inhibitors might negatively impact the progression of HIV-related heart failure(HF),which complicates the determination of the best therapy strategy for HIVassociated *** objective of this review is to examine the pathophysiology and correlation of various antiretroviral drugs leading to HIV-associated ***,we explore the causes of HIV-associated atherosclerotic cardiovascular disease,including the high frequency of classic cardiovascular risk factors in HIVinfected patients,as well as HIV-related factors like the use of ART and chronic inflammation despite successful treatment of HIV *** studies have revealed that individuals living with HIV/acquired immune deficiency syndrome frequently experience *** conclusion,despite advancements in HIV care,HIV-infected individuals continue to face an increased risk of HIV-associated cardiomyopathy and *** research is necessary to comprehend the underlying causes and develop effective treatments for cardiovascular disease in this *** also discuss the currently available therapeutic options and ongoing research to mitigate the risk of cardiovascular disease and

关键词： Antiretroviral therapy Cardiac disorders Myocardial infarction cardiomyopathy Heart failure HIV/AIDS Myocardial infarction

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Impact of vericiguat on heart failure with reduced ejection fraction:a review

引用

Global Health Journal 2023年第3期7卷 123-129页

作者： Manisha Vohra Mohammad Amir Ian Osoro Amit Sharma Ranjeet Kumar Department of Pharmacy Practice ISF College of PharmacyMogaPunjab 142001India

Introduction:Heart failure is a major public health issue with a prevalence of about 26 million people *** nitric oxide availability,lower soluble guanylate cyclase(sGC)activity,and decreased cyclic guanosine monophosphate(cGMP)production are the causes of HF's *** prescribed under the brand name Verquvo was approved by *** and Drug Administration(FDA)in January *** is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction(HFrEF).Objective:The mechanism of action(cGMP pathway)of vericiguat,its clinical trials,its use in the treatment of heart failure,and its possible future aspects in therapeutic recommendations are all covered in this *** will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters,dosing,administration,and drug-related problems of this new ***:Various databases for drug review were used in this review like PubMed,Medline,Google scholar,Drug bank,***,Medscape,and European society of cardiology guidelines.A total of 58 articles were screened out of which 39 articles were included in this ***:This review discusses vericiguat's mechanism of action(cGMP pathway),clinical studies,application in the treatment of heart failure,and potential future considerations in therapeutic *** will also educate healthcare professionals about the new drug's pharmacokinetics and pharmacodynamics,dose,administration,and drug-related ***:After hospitalization for HFrEF,the 5-year survival rate is just 25%,and disease morbidity and death are stil *** adjunctive therapy for individuals with heart failure and a low ejection fraction,vericiguat has a moderate level of ***'s efficacy as an adjunct therapy to different drugs used to cure HF has to be further ***'s safety and dosage in patients w

关键词： Vericiguat Heart failure with reduced ejection fraction Soluble guanylate cyclase stimulator Nitric oxide Cyclicguanosinemonophosphate

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：